JNJ Inks Licensing Deal With Kaken for Eczema Candidate KP-723

Zacks2024-12-27

Johnson & Johnson JNJ announced entering into an exclusive global licensing agreement with Kaken Pharmaceutical to develop, manufacture and commercialize the latter’s STAT6 program for autoimmune and ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2494385582?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-27 20:17","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2494385582","market":"us","top_or_hot":-1,"title":"JNJ Inks Licensing Deal With Kaken for Eczema Candidate KP-723","media":"Zacks","content":"<div>\n<p>Johnson & Johnson JNJ announced entering into an exclusive global licensing agreement with Kaken Pharmaceutical to develop, manufacture and commercialize the latter’s STAT6 program for autoimmune and ...</p>\n\n<a href=\"https://finance.yahoo.com/news/jnj-inks-licensing-deal-kaken-121700393.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JNJ Inks Licensing Deal With Kaken for Eczema Candidate KP-723</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJNJ Inks Licensing Deal With Kaken for Eczema Candidate KP-723\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-27 20:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/jnj-inks-licensing-deal-kaken-121700393.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Johnson & Johnson JNJ announced entering into an exclusive global licensing agreement with Kaken Pharmaceutical to develop, manufacture and commercialize the latter’s STAT6 program for autoimmune and ...</p>\n\n<a href=\"https://finance.yahoo.com/news/jnj-inks-licensing-deal-kaken-121700393.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1057294990.SGD","symbol_name":"Blackrock World Healthscience A2 SGD-H","start_time":0,"source_url":"https://finance.yahoo.com/news/jnj-inks-licensing-deal-kaken-121700393.html","article_id":"2494385582","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2494385582","pubTimestamp":1735301820,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"How the Licensing Deal for the AD Program Benefits JNJ. The licensing deal with Kaken reinforces Johnson & Johnson’s dedication to targeting disease-specific pathways across diverse patient populations, leveraging innovative mechanisms and approaches to revolutionize the treatment of AD and other autoimmune and allergic conditions.Per JNJ, most AD patients fail to achieve remission with currently available treatments, representing a huge unmet medical need. The company believes that the STAT6 program stands out as a promising research area, offering the potential for a safe and effective novel oral therapy for those suffering from AD and other autoimmune diseases.In the past three months, shares of JNJ have lost 10.2% compared with the industry’s 13.8% decline.Some better-ranked stocks from the sector areCastle BiosciencesCSTL,CytomX TherapeuticsCTMX andSpero TherapeuticsSPRO, each sporting a Zacks Rank #1  at present. You can seethe complete list of today’s Zacks #1 Rank stocks here.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4588":"碎股","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","SPRO":"Spero Therapeutics Inc.","LU1221951046.USD":"NORDEA 1 STABLE RETURN \"HM\" (USDHDG) INC","IE00BDGV0183.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) INC","LU1261432733.SGD":"Fidelity World A-ACC-SGD","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","LU1221951129.SGD":"NORDEA 1 STABLE RETURN \"HM\" (SGDHDG) INC","LU0058720904.USD":"联博国际健康护理基金A","SG9999002224.SGD":"Allianz Global High Payout SGD","BK4581":"高盛持仓","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1196500208.SGD":"NORDEA STABLE RETURN \"HB\" (SGDHDG) ACC","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","LU1674673691.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (USD) INC","LU0122379950.USD":"贝莱德世界健康科学A2","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU1674673428.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AC\" (USD) ACC","IE00BGHQF631.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) ACC","LU1778281490.HKD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (HKD) INC","CTMX":"CytomX","IE00B3PB1722.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) INC","CSTL":"Castle Biosciences, Inc.","BK4532":"文艺复兴科技持仓","JNJ":"强生","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU0345770993.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) INC","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4585":"ETF&股票定投概念","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","BK4139":"生物科技","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","BK4196":"保健护理服务","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc"},"translate_title":"JNJ与Kaken签署湿疹候选药物KP-723许可协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SPRO":1,"CSTL":1,"CTMX":1,"JNJ":1},"content_text":"Johnson & Johnson JNJ announced entering into an exclusive global licensing agreement with Kaken Pharmaceutical to develop, manufacture and commercialize the latter’s STAT6 program for autoimmune and allergic diseases, including atopic dermatitis (AD). The licensing deal for Kaken’s STAT6 program includes global rights to its lead candidate, KP-723.\nHow the Licensing Deal for the AD Program Benefits JNJ\nThe licensing deal with Kaken reinforces Johnson & Johnson’s dedication to targeting disease-specific pathways across diverse patient populations, leveraging innovative mechanisms and approaches to revolutionize the treatment of AD and other autoimmune and allergic conditions.\nPer JNJ, most AD patients fail to achieve remission with currently available treatments, representing a huge unmet medical need. The company believes that the STAT6 program stands out as a promising research area, offering the potential for a safe and effective novel oral therapy for those suffering from AD and other autoimmune diseases.\nIn the past three months, shares of JNJ have lost 10.2% compared with the industry’s 13.8% decline.\nImage Source: Zacks Investment Research\nJohnson & Johnson is currently gearing up to initiate a phase I study on KP-723 to treat AD in 2025. The company also expects to investigate the candidate in other Th2-mediated diseases, including asthma, in the future. The candidate is being developed as an oral pill for AD, which is expected to ensure convenience of use and hence better patient compliance.\nAD, also known as eczema, is a chronic inflammatory skin disorder that affects more than 9.6 million children and 16.5 million adults in the United States. It causes itching and inflammation that can worsen with scratching. AD takes a serious toll on the quality of life of people suffering from it. In the worst cases, it may also lead to suicide.\nKaken retains KP-723’s commercialization rights in Japan, where Johnson & Johnson can enter into a co-promotion agreement with Kaken. In consideration of the licensing agreement, Kaken is eligible to receive an equity investment from Johnson & Johnson.\nIn 2024, JNJ added other development candidates to its dermatology pipeline, with differentiated mechanisms of action to treat AD through acquisitions. These additions highlight the company’s strategic focus on developing a portfolio of distinct and complementary bispecifics targeting multiple key disease-driving pathways in treating AD and other immune-mediated diseases.\n\nJohnson & Johnson Price and Consensus\n\nJohnson & Johnson price-consensus-chart | Johnson & Johnson Quote\n\nJNJ’s Zacks Rank & Stocks to Consider\nJohnson & Johnson currently carries a Zacks Rank #3 (Hold).\nSome better-ranked stocks from the sector are Castle Biosciences CSTL, CytomX Therapeutics CTMX and Spero Therapeutics SPRO, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.\nIn the past 60 days, 2024 estimates for Castle Biosciences have improved from a loss of 59 cents per share to earnings of 34 cents. During the same timeframe, loss per share estimates for 2025 have narrowed from $2.15 to $1.84. In the past three months, shares of Castle Biosciences have lost 5%.\nCSTL’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 172.72%.\nIn the past 60 days, estimates for CytomX Therapeutics’ 2024 loss per share have narrowed from 29 cents to 5 cents. Estimates for 2025 loss per share have narrowed from 56 cents to 35 cents during the same timeframe. In the past three months, CTMX stock has lost 3.4%.\nCytomX’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 115.70%.\nIn the past 60 days, estimates for Spero Therapeutics’ 2024 loss per share have narrowed from $1.59 to $1.29. Estimates for 2025 loss per share have narrowed from $1.54 to 79 cents during the same timeframe. In the past three months, Spero’s shares have lost 29.6%.\nSPRO’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 94.42%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nJohnson & Johnson (JNJ) : Free Stock Analysis Report\nCytomX Therapeutics, Inc. (CTMX) : Free Stock Analysis Report\nSpero Therapeutics, Inc. (SPRO) : Free Stock Analysis Report\nCastle Biosciences, Inc. (CSTL) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2494385582"}